Hydroxychloroquine and Mortality Among Patients With Systemic Lupus Erythematosus in the General Population.
April M JorgeNatalie McCormickNa LuYufei ZhengJohn EsdaileMary A De VeraHyon K ChoiJuan Antonio Aviña-ZubietaPublished in: Arthritis care & research (2021)
Our general population data support a substantial survival benefit associated with current HCQ use. Increased mortality among patients who had discontinued HCQ recently could be due to a sick stopper effect or the loss of actual HCQ benefits.